New Longer-Term Safety Data of Chugai’s Satralizumab in Adults and Adolescents with Neuromyelitis Optica Spectrum Disorder Presented at EAN


Please refer to the link below for details of the press release:

- New longer-term data reinforce safety of Roche’s satralizumab in adults and adolescents with neuromyelitis optica spectrum disorder

###